Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study

计划入组 50 人 · 首次发布于 2025 年 5 月 25 日

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

计划入组 12 人 · 首次发布于 2012 年 11 月 22 日

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

计划入组 50 人 · 首次发布于 2024 年 3 月 15 日

Nadofaragene firadenovec-vncg(Adstiladrin)

in situ autologous dendritic cell therapy (liver cancer)

Cis-urocanic acid

CIS BIO INTERNATIONAL

France

In His Image

United States

Partners In Health

United States

Phase II Study Evaluates Durvalumab for BCG-Unresponsive Bladder Cancer

Protara Therapeutics' TARA-002 Shows Promise in Bladder Cancer Trial

Hexvix Receives Marketing Approval in China for Bladder Cancer Detection